Guía de recomendaciones para el tratamiento de la colitis ulcerosa y la enfermedad de Crohn en pacientes adultos

Ulcerative colitis and Crohn's disease are chronic conditions that can take a potentially severe or even life-threatening course, with high morbidity stemming from their complications. These diseases affect not only physical health but also significantly impact the quality of life of patients and their families. The primary goal of these guidelines is to provide treating physicians with clear, up-to-date information regarding the quality and strength of evidence supporting each therapeutic option. The document is intended to support shared clinical decision-making, empowering healthcare providers and patients to jointly develop a personalized treatment plan tailored to individual needs, preferences, and clinical characteristics. Although epidemio-logical data on inflammatory bowel disease (IBD) in Latin America remain limited, multiple studies have highlighted a substantial disease burden across the region, along with ongoing challenges in diagnosis, access to advanced therapies, and long-term management. In response to these needs -and recognizing the continuous advances in therapeutic strategies- the Chilean Working Group on Crohn's Disease and Ulcerative Colitis (ACTECCU) undertook the development of clinical guidelines aimed at the treatment of IBD in adult patients. The guideline was developed through a systematic review of the best available evidence, enriched by the active participation of a national panel of specialists who contributed their clinical expertise in the comprehensive management of IBD. Ultimately, these guidelines aim to optimize the management of IBD in Chile, promote more equitable access to evidence-based treatments, and improve health outcomes and quality of life for those living with these chronic conditions.